Table 4 Second-line therapy after nab-paclitaxel and atezolizumab.
Treatment | Patients, n (%) |
|---|---|
Patients receiving a second-line therapy: | 31 (59.6) |
• Carboplatin-based regimen | 8 (25.8) |
• Capecitabine | 7 (22.6) |
• Anthracycline-based regimen | 5 (16.1) |
• Eribulin | 5 (16.1) |
• Olaparib | 3 (9.7) |
• Docetaxel | 1 (3.2) |
• CMF | 1 (3.2) |
• Ipatasertib | 1 (3.2) |
